Novel plasma biomarkers improve discrimination of metabolic health independent of weight
Abstract We sought to determine if novel plasma biomarkers improve traditionally defined metabolic health (MH) in predicting risk of cardiovascular disease (CVD) events irrespective of weight. Poor MH was defined in CATHGEN biorepository participants (n > 9300), a follow-up cohort (> 5600 days...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-12-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-020-78478-w |
id |
doaj-9c242d1b2a20418c81d4a2dbd61f3aa3 |
---|---|
record_format |
Article |
spelling |
doaj-9c242d1b2a20418c81d4a2dbd61f3aa32020-12-08T13:24:03ZengNature Publishing GroupScientific Reports2045-23222020-12-011011910.1038/s41598-020-78478-wNovel plasma biomarkers improve discrimination of metabolic health independent of weightStephen Ellison0Jawan W. Abdulrahim1Lydia Coulter Kwee2Nathan A. Bihlmeyer3Neha Pagidipati4Robert McGarrah5James R. Bain6William E. Kraus7Svati H. Shah8Department of Anesthesiology, Duke University Medical CenterDuke Molecular Physiology Institute, Duke University School of MedicineDuke Molecular Physiology Institute, Duke University School of MedicineDuke Molecular Physiology Institute, Duke University School of MedicineDivision of Cardiology, Department of Medicine, Duke University School of MedicineDuke Molecular Physiology Institute, Duke University School of MedicineDuke Molecular Physiology Institute, Duke University School of MedicineDuke Molecular Physiology Institute, Duke University School of MedicineDuke Molecular Physiology Institute, Duke University School of MedicineAbstract We sought to determine if novel plasma biomarkers improve traditionally defined metabolic health (MH) in predicting risk of cardiovascular disease (CVD) events irrespective of weight. Poor MH was defined in CATHGEN biorepository participants (n > 9300), a follow-up cohort (> 5600 days) comprising participants undergoing evaluation for possible ischemic heart disease. Lipoprotein subparticles, lipoprotein-insulin resistance (LP-IR), and GlycA were measured using NMR spectroscopy (n = 8385), while acylcarnitines and amino acids were measured using flow-injection, tandem mass spectrometry (n = 3592). Multivariable Cox proportional hazards models determined association of poor MH and plasma biomarkers with time-to-all-cause mortality or incident myocardial infarction. Low-density lipoprotein particle size and high-density lipoprotein, small and medium particle size (HMSP), GlycA, LP-IR, short-chain dicarboxylacylcarnitines (SCDA), and branched-chain amino acid plasma biomarkers were independently associated with CVD events after adjustment for traditionally defined MH in the overall cohort (p = 3.3 × 10−4–3.6 × 10−123), as well as within most of the individual BMI categories (p = 8.1 × 10−3–1.4 × 10−49). LP-IR, GlycA, HMSP, and SCDA improved metrics of model fit analyses beyond that of traditionally defined MH. We found that LP-IR, GlycA, HMSP, and SCDA improve traditionally defined MH models in prediction of adverse CVD events irrespective of BMI.https://doi.org/10.1038/s41598-020-78478-w |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Stephen Ellison Jawan W. Abdulrahim Lydia Coulter Kwee Nathan A. Bihlmeyer Neha Pagidipati Robert McGarrah James R. Bain William E. Kraus Svati H. Shah |
spellingShingle |
Stephen Ellison Jawan W. Abdulrahim Lydia Coulter Kwee Nathan A. Bihlmeyer Neha Pagidipati Robert McGarrah James R. Bain William E. Kraus Svati H. Shah Novel plasma biomarkers improve discrimination of metabolic health independent of weight Scientific Reports |
author_facet |
Stephen Ellison Jawan W. Abdulrahim Lydia Coulter Kwee Nathan A. Bihlmeyer Neha Pagidipati Robert McGarrah James R. Bain William E. Kraus Svati H. Shah |
author_sort |
Stephen Ellison |
title |
Novel plasma biomarkers improve discrimination of metabolic health independent of weight |
title_short |
Novel plasma biomarkers improve discrimination of metabolic health independent of weight |
title_full |
Novel plasma biomarkers improve discrimination of metabolic health independent of weight |
title_fullStr |
Novel plasma biomarkers improve discrimination of metabolic health independent of weight |
title_full_unstemmed |
Novel plasma biomarkers improve discrimination of metabolic health independent of weight |
title_sort |
novel plasma biomarkers improve discrimination of metabolic health independent of weight |
publisher |
Nature Publishing Group |
series |
Scientific Reports |
issn |
2045-2322 |
publishDate |
2020-12-01 |
description |
Abstract We sought to determine if novel plasma biomarkers improve traditionally defined metabolic health (MH) in predicting risk of cardiovascular disease (CVD) events irrespective of weight. Poor MH was defined in CATHGEN biorepository participants (n > 9300), a follow-up cohort (> 5600 days) comprising participants undergoing evaluation for possible ischemic heart disease. Lipoprotein subparticles, lipoprotein-insulin resistance (LP-IR), and GlycA were measured using NMR spectroscopy (n = 8385), while acylcarnitines and amino acids were measured using flow-injection, tandem mass spectrometry (n = 3592). Multivariable Cox proportional hazards models determined association of poor MH and plasma biomarkers with time-to-all-cause mortality or incident myocardial infarction. Low-density lipoprotein particle size and high-density lipoprotein, small and medium particle size (HMSP), GlycA, LP-IR, short-chain dicarboxylacylcarnitines (SCDA), and branched-chain amino acid plasma biomarkers were independently associated with CVD events after adjustment for traditionally defined MH in the overall cohort (p = 3.3 × 10−4–3.6 × 10−123), as well as within most of the individual BMI categories (p = 8.1 × 10−3–1.4 × 10−49). LP-IR, GlycA, HMSP, and SCDA improved metrics of model fit analyses beyond that of traditionally defined MH. We found that LP-IR, GlycA, HMSP, and SCDA improve traditionally defined MH models in prediction of adverse CVD events irrespective of BMI. |
url |
https://doi.org/10.1038/s41598-020-78478-w |
work_keys_str_mv |
AT stephenellison novelplasmabiomarkersimprovediscriminationofmetabolichealthindependentofweight AT jawanwabdulrahim novelplasmabiomarkersimprovediscriminationofmetabolichealthindependentofweight AT lydiacoulterkwee novelplasmabiomarkersimprovediscriminationofmetabolichealthindependentofweight AT nathanabihlmeyer novelplasmabiomarkersimprovediscriminationofmetabolichealthindependentofweight AT nehapagidipati novelplasmabiomarkersimprovediscriminationofmetabolichealthindependentofweight AT robertmcgarrah novelplasmabiomarkersimprovediscriminationofmetabolichealthindependentofweight AT jamesrbain novelplasmabiomarkersimprovediscriminationofmetabolichealthindependentofweight AT williamekraus novelplasmabiomarkersimprovediscriminationofmetabolichealthindependentofweight AT svatihshah novelplasmabiomarkersimprovediscriminationofmetabolichealthindependentofweight |
_version_ |
1724389291262476288 |